Trane Technologies 株価情報 (NYSE: TT)

Trane Technologies (NYSE:TT) 株価情報

Trane Technologies

Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The $20 billion company generates approximately 70% of sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for over 80% of its revenue.

Trane Technologies PLC

ThunderCore

Terveystalo PLC

Titan America SA

ServiceTitan, Inc. - Class A Common Stock

ServiceTitan Inc

TTW PUBLIC CO ORD by TTW Public Company Limited

TTW PCL

TTW PCL UNSP/ADR by TTW Public Company Limited

TRITAX EUROBOX PLC by Tritax Eurobox PLC

Tata Consumer Products Ltd GDR

2020 Bulkers Ltd

Total Brain Ltd

TRITAX BIG BOX REIT PLC by Tritax Big Box Reit Plc

The Toro Co

TS Tech Co Ltd

Tattooed Chef Inc

TITAN CEM INTL NV REG SHS by TITAN CEM INTL N V

Titan Cement International SA

Tautachrome Inc

The Trade Desk, Inc. - Class A Common Stock

The Trade Desk Inc

TDK Corp

TotalEnergies SE

TTEC Holdings Inc

Tetra Tech Inc

T. Rowe Price Technology ETF

TEST SEC T by Test Comp

TietoEVRY Corp

BULLION GOLD RES ORD by Bullion Gold Resources Corp.

Bullion Gold Resources Corp

TASTE GOURMET GROUP LTD by TASTE GOURMET GROUP LTD.

Taste Gourmet Group Ltd

TT ELECTRONICS PLC ORD by TT Electronics PLC

TT Electronics PLC

TechTarget Inc

TRANS CANADA GOLD CORP by Trans Canada Gold Corp.

Trans Canada Gold Corp

TITANIUM HLDGS GROUP INC by Titanium Holdings Group, Inc.

Titanium Holdings Group Inc

TETHYS OIL AB by Tethys Oil AB

Tetra Technologies Inc

THIOGENESIS THERAPEUTICS by Thiogenesis Therapeutics Corp.

Thiogenesis Therapeutics Corp

TERTIARY MINERALS PLC ORD by Tertiary Minerals Plc

Tertiary Minerals PLC

Total Helium Ltd

Total Telcom Inc

TANTALEX LITHIUM RES CP by Tantalex Lithium Resources Corporation

Tantalex Lithium Resources Corp

TTM Technologies Inc

DIGITAL TELECOMM INFR UT by Digital Telecommunications Infrastructure FD

TRITON MINERALS LTD by Triton Minerals Ltd.

Triton Minerals Ltd

Datable Technology Corp

DATABLE TECHNOLOGY CORP by Datable Technology Corp.

TECHTRONIC INDUS CO ORD by Techtronic Industries Ltd.

Techtronic Industries Co Ltd

TECHTRONIC INDUS LTD ADR by Techtronic Industries Ltd.

TITANIUM TRANSPRTATION GP by Titanium Transportation Group

Titanium Transportation Group Inc

Titan NRG

TOHO TITANIUM CO LTD by Toho Titanium Co. Ltd.

Toho Titanium Co Ltd

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc Warrants - Class B (18/10/2024)

TITANIUM GROUP LTD by Titanium Group, Ltd.

T2 Biosystems Inc

Tortoise Pipeline & Energy Fund Inc. Com (New)

Telstra Group Ltd

TERRA ENERGY CORP ORD by Terra Energy Corp.

TURK TRAKTOR VE Z/M AS by Turk Traktor Ve Ziraat Makineleri AS

Turk Traktor ve Ziraat Makineleri AS

Tile Shop Holdings Inc

TARTISAN NICKEL CORP by Tartisan Nickel Corp.

Tartisan Nickel Corp

ProShares UltraPro Short 20 Year Treasury

The Transfer Token

Titan Minerals Ltd

TITAN MINERALS LTD by Titan Minerals Ltd.

NEXXEN INTERNATIONAL LTD by Nexxen International Ltd.

Treatt PLC

TRUTRACE TECH CORP by Trutrace Technologies Inc.

TruTrace Technologies Inc

TOKYU FUDOSAN HLDGS CRP by Tokyu Fudosan Holdings Corp

Tokyu Fudosan Holdings Corp

Totvs SA

Take-Two Interactive Software, Inc. - Common Stock

Take-Two Interactive Software Inc

TTW PUBLIC CO FGN REG by TTW Public Company Limited

TTW PCL NON VTG D/R by TTW Public Company Limited

TRILLIANT EXPL CORP NEW by Trilliant Exploration Corp.

TRINITY PETE TRUST CBI by Trinity Petroleum Trust

Trinity Petroleum Trust

Biotech

News

General

BDRX

Biodexa Announces Upcoming Issuance Of U.S. Patent For Oral Rapamycin Nanoparticle Preparations

TSLA

"Tesla To Roll Out Software Update To China EV Owners In Batches; Prepares To Deploy Long-Awaited FSD Features In China; Tesla Plans Software Update W/ Assisted Driving For City Roads"

Shares of Youdao Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) fell slightly following the company's fourth-quarter results, mainly on profit-taking with the stock having <a href="https://www.benzinga.com/quote/DAO">climbed almost 45% over the past month</a>.
The results came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here's a deep dive into Youdao's financial release.
Analyst Ratings For Youdao
The company is known for its online platform that focuses on providing learning tools and services. Powered by AI, the platform has been developed by internet services company NetEase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>).
Morgan Stanley, Jefferies and Citigroup have a Buy rating on Youdao. Check out <a href="https://www.benzinga.com/analyst-ratings/analyst-color">other analyst stock ratings</a>.
Youdao: Highlights Of Financial Release
For the fourth quarter, Youdao reported net revenues of RMB 1.3 billion ($180 million), down 9.5% year-on-year. Management indicated that the top-line contraction was mainly due to a decline in revenues from learning services.
Despite the decline in revenues, profitability improved in the quarter. Income from operations reached RMB 84.2 million ($11.6 million), representing 10.3% year-on-year growth.
The Chinese company reported earnings of 70 cents per share for the fourth quarter, significantly beating the consensus estimate of 54 cents per share by 30.6%.
For the full year, net revenues reached RMB 5.6 billion ($770 million), up 4.4% year-on-year. Income from operations reached RMB 148.8 million ($20.51 million), compared to a loss of RMB 466.3 million ($64.26 million) in 2023.
Management said that Youdao Lingshi, the service that provides online learning courses, improved customer loyalty in the fourth quarter. Backed by Youdao Lingshi's AI-powered tiered learning videos and learning counseling, retention rates surpassing 70% in the fourth quarter, marking a year-over-year improvement of over 5 percentage points.
The company also indicated that the transition from larger to smaller classes had driven an over 20% year-on-year increase in gross billings in the fourth quarter.
Youdao Desktop Translation won the "Best Online Education App Award" at the Microsoft Store 2024 Annual App Awards.
Youdao Leverages DeepSeek
On February 6, Youdao announced the full deployment of DeepSeek-R1 in its learning apps, courses, ad platforms and hardware devices.
Mr. P AI Tutor, Youdao's popular tool that provides deeper insights into learning materials, is being powered by DeepSeek-R1 to offer "a faster, more responsive, and cost-efficient service," the company said in a statement.
Mr. P AI Tutor is available in several languages. The company said that the "long reasoning chains offered by DeepSeek-R1" has helped Mr. P AI Tutor to improve its personalized Q&amp;A capabilities, "providing deeper and more accurate solutions and significantly upgrading the user experience." The company plans to launch Mr. P AI Tutor 2.0 in the near term.
DeepSeek's advanced reasoning capabilities are fully deployed in other products, like SpaceOne.
Youdao has also introduced the&nbsp;SpaceOne full-screen tutoring device, an AI-powered learning tool designed for students and professionals.
"We believe that large AI models should serve not merely as additional features, but as autonomous agents that drive outcomes," CEO Feng Zhou said during the earnings call. He added that Youdao plans to launch an "AI Native" strategy, which involves "leveraging AI as a foundational layer across our business lines."
DAO Price Action: Shares of Youdao had declined by 1.25% to close at $10.26 on Friday.
Photo: Shutterstock

Earnings

Earnings Beats

Analyst Ratings

NTES

Youdao Turns Profitable In 2024, Leveraging DeepSeek To Upgrade User Experience In Learning

Ovintiv's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) short percent of float has risen 9.77% since its last report. The company recently reported that it has 5.45 million shares sold short, which is 2.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ovintiv Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740403827_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ovintiv has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ovintiv's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ovintiv's peer group average for short interest as a percentage of float is 6.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Ovintiv?

Fabrinet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) short percent of float has fallen 8.9% since its last report. The company recently reported that it has 1.89 million shares sold short, which is 7.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Fabrinet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740403822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fabrinet has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Fabrinet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Fabrinet's peer group average for short interest as a percentage of float is 2.53%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Fabrinet?

Monster Beverage's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NYSE">MNST</a>) short percent of float has fallen 9.68% since its last report. The company recently reported that it has 21.12 million shares sold short, which is 3.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Monster Beverage Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740403817_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monster Beverage has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Monster Beverage's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Monster Beverage's peer group average for short interest as a percentage of float is 7.80%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MNST

Is the Market Bullish or Bearish on Monster Beverage?

Macro Economic Events

Econ #s

Economics

Chicago Fed National Activity For January -0.03 Vs 0.18 Prior

Foresight to equip autonomous drones and unmanned aerial vehicles with NVIDIA Jetson Orin platform for enhanced real-time perception, obstacle detection, and energy efficiency across diverse applications
NESS ZIONA, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) ("Foresight" or the "Company"), a leading innovator in 3D perception systems, announces the integration of&nbsp;<a href="https://www.globenewswire.com/Tracker?data=EYnd-9aPlpwAr7IZ7aw2T1DeOrdBb2Q75D0yXrXvT3nKz3L0DrwOCQlTIUpZ1TT6xfvXfOKgfefmhyBw9W5I-yDismNEP95dXHU1zLJTlpL8bColWucGCFIgizN-vHqe7rmjc72vr1cts5lc_esjmQ==">NVIDIA</a><a href="https://www.globenewswire.com/Tracker?data=YMhAtmI-xF5GiSWXq1yhZqwWx9I2OfqyHzG9dtpBZUwTvLgrWjgY6j0rjTWORLqq-HhBTaY021kzZLJLE0SPw-G0h1wG0VLg0NYLgitBavzW-QVm6J9kIiMcBzzVuqwoXuUafOSw4YO5Lssvq9Bcp_LnHPYpldrchx2v8pJSl54="> Jetson Orin</a> computing platforms into its cutting-edge perception technologies.
The collaboration leverages NVIDIA Jetson Orin Nano and NVIDIA Jetson AGX Orin platforms to enhance the capabilities of Foresight's 3D perception systems across various industries, with focus on autonomous drone and unmanned aerial vehicles (UAV).

FRSX

Foresight To Equip Autonomous Drones And Unmanned Aerial Vehicles With NVIDIA Jetson Orin Platform For Enhanced Real-Time Perception, Obstacle Detection, And Energy Efficiency Across Diverse Applications

Piper Sandler analyst Korinne Wolfmeyer maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Neutral and lowers the price target from $173 to $172.

Price Target

Piper Sandler Maintains Neutral on Procter & Gamble, Lowers Price Target to $172

Piper Sandler analyst Korinne Wolfmeyer maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Overweight and raises the price target from $24 to $27.

KVUE

Piper Sandler Maintains Overweight on Kenvue, Raises Price Target to $27

Fresh Del Monte Produce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading lower in premarket</a> on Monday.
The company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43907839/fresh-del-monte-produce-inc-reports-fourth-quarter-and-full-fiscal-year-2024-financial-results" rel="noreferrer noopener">fourth-quarter sales growth</a> of 0.4% year-on-year to $1.01 billion, missing the analyst consensus estimate of $1.03 billion.
The increase in net sales was driven by higher net sales in the company&#8217;s fresh and value-added products segment, primarily due to higher per unit selling prices.
Adjusted EPS of $0.26 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the analyst consensus of $0.37.</a>
Gross profit jumped 9.9% Y/Y to $68.7 million, and the profit margin expanded 60 basis points to 6.8%.
The operating margin was 3%, and operating income for the quarter was $30.3 million versus an operating loss of $113.4 million last year.
Adjusted EBITDA decreased to $35.2 million versus $37.8 million last year. Adjusted EBITDA margin was 3.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success" rel="noreferrer noopener">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a>
The operating cash flow for the twelve months totaled $182.5 million.
The company&#8217;s Board of Directors <a href="https://www.benzinga.com/pressreleases/25/02/b43907584/fresh-del-monte-produce-inc-announces-150-million-share-repurchase-program-and-increases-quarterly" target="_blank" rel="noreferrer noopener">approved an increase in the quarterly</a> dividend from $0.25 to $0.30. The next quarterly dividend will be paid on March 28, 2025, to shareholders of record on March 10, 2025. Additionally, the Board also approved a $150 million share repurchase program
The company held $32.6 million in cash and equivalents as of December 27, 2024. Long term debt as of the end of 2024 decreased to $244.1 million from $400.0 million as of the prior-year end.
&#8220;Our full-year 2024 results reflect the effectiveness of our strategic focus and operational improvements. This success, achieved despite facing several challenges in 2024, was primarily driven by the exceptional performance of our fresh and value-added products segment, particularly pineapples, avocados, and fresh-cut fruit, which continue to fuel our growth and deliver strong gross margins for the Company,&#8221; said Mohammad Abu-Ghazaleh, Fresh Del Monte&#8217;s Chairman and CEO.
Price Action: FDP shares are trading lower by 3.53% at $29.79 in premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios" target="_blank" rel="noreferrer noopener">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a></li>
</ul>
Image via Shutterstock.

Guidance

Dividends

Buybacks

Movers

Fresh Del Monte Stock Falls As Q4 Sales & Earnings Miss Expectations

Piper Sandler analyst Korinne Wolfmeyer maintains Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) with a Overweight and lowers the price target from $9 to $8.

COTY

Piper Sandler Maintains Overweight on Coty, Lowers Price Target to $8

ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) will release its fourth-quarter financial results, after the closing bell, on <a href="https://www.benzinga.com/quote/OKE/earnings">Monday, Feb. 24, 2025</a>.
Analysts expect the Denver, Colorado-based company to report quarterly earnings at $1.04 per share, up from 50 cents per share in the year-ago period. ONEOK projects quarterly revenue of $5.3 billion, compared to $3.96 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 4, ONEOK announced joint ventures with MPLX to build LPG export terminal in Texas City, Texas.
With the recent buzz around ONEOK, some investors may be eyeing potential gains from the company's dividends too. As of now, ONEOK offers an annual dividend yield of 4.20%, which is a quarterly dividend amount of $1.03 per share ($4.12 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $142,834 or around 1,456 shares. For a more modest $100 per month or $1,200 per year, you would need $28,547 or around 291 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.12 in this case). So, $6,000 / $4.12 = 1,456 ($500 per month), and $1,200 / $4.12 = 291 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
OKE Price Action: Shares of ONEOK fell 0.5% to close at $98.10 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month">Top 2 Health Care Stocks That May Rocket Higher This Month</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

How To Earn $500 A Month From ONEOK Stock Ahead Of Q4 Earnings

On Saturday, Teva Pharmaceuticals Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV&#8217;574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn&#8217;s disease (CD), the two most common forms of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43900182/teva-and-sanofi-present-new-positive-phase-2b-study-results-at-ecco-2025-reinforcing-best-in-class" rel="noreferrer noopener">inflammatory bowel disease (IBD)</a>.
These results were shared at the Congress of the European Crohn&#8217;s and Colitis Organisation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As &#8216;Top Pick For 2025&#8217;</a>
Ulcerative colitis
<ul>
<li>In the UC cohort of the RELIEVE UCCD study, 36% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission (mMS) at week 14 compared to 20% treated with placebo.</li>
<li>Placebo-adjusted rates were 16% (450 mg) and 27% (900 mg) (p=0.050 and 0.003, respectively).
<ul>
<li>Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy (AT)-experienced and AT-naïve subgroups of patients.AT-experienced: 29% (450 mg) and 36% (900 mg), with placebo-adjusted rates of 22% (450 mg) and 29% (900 mg).</li>
<li>AT-naïve: 39% (450 mg) and 53% (900 mg), with placebo-adjusted rates of 12% (450 mg) and 26% (900 mg).1-3</li>
</ul>
</li>
</ul>
Crohn&#8217;s disease
<ul>
<li>In the CD cohort of the RELIEVE UCCD study, 26% (450 mg) and 48% (900 mg) of patients with CD treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD) compared to 13% on placebo.</li>
<li>Placebo-adjusted rates were 13% (450 mg) and 35% (900 mg) at week 14 (p=0.058 and &lt;0.001, respectively).
<ul>
<li>Higher endoscopic response rates were observed for both doses of duvakitug versus placebo in both AT-experienced and -naïve subgroups of patients.AT-experienced: 11% (450 mg) and 48% (900 mg), with placebo-adjusted rates of 7% (450 mg) and 44% (900 mg).</li>
<li>AT-naïve: 47% (450 mg) and 47% (900 mg), with placebo-adjusted rates of 25% (450 mg) and 25% (900 mg).</li>
</ul>
</li>
</ul>
The company expects to start the Phase 3 program in the second half of 2025.
Price Action: TEVA stock is down 0.18% at $16.70, and SNY stock is down 0.48% at $54.20 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43901425/apple-bows-out-of-uks-cloud-encryption-amid-governments-backdoor-demands" target="_blank" rel="noreferrer noopener">Apple Bows Out of UK&#8217;s Cloud Encryption Amid Government&#8217;s &#8216;Backdoor&#8217; Demands</a></li>
</ul>
Photo by Ralf Liebhold via Shutterstock

Large Cap

Health Care

TEVA

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Stephens &amp; Co. analyst John Campbell maintains Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) with a Overweight and raises the price target from $68 to $75.

Stephens & Co. Maintains Overweight on Fidelity National Finl, Raises Price Target to $75

OPTT

Ocean Power Technologies Announces Successful Demonstration Of Defense And Security Capabilities At NAVDEX. Showcasing WAM-V Unmanned Surface Vehicles, Next Generation Powerbuoy, And AI Capable Merrows

Manulife Financial Corporation ("Manulife") announced today that it has&nbsp;entered into an automatic share repurchase plan (the "automatic plan") under which its designated broker will repurchase Manulife's common shares pursuant to its previously announced normal course issuer bid ("NCIB"). The actual number of common shares purchased under the automatic plan, the timing of such purchases and the price at which common shares are purchased will depend upon future market conditions. The automatic plan, which was pre-cleared by the TSX, provides for the potential repurchase of common shares at any time, including when Manulife ordinarily would not be active in the market due to its own internal trading blackout periods, insider trading rules, or otherwise.

Manulife Initiates Automatic Share Repurchase Plan Under Normal Course Issuer Bid; No Terms Disclosed

Stephens &amp; Co. analyst Sudan Loganathan maintains ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) with a Overweight and raises the price target from $6 to $8.

ADCT

Stephens & Co. Maintains Overweight on ADC Therapeutics, Raises Price Target to $8

Piper Sandler analyst Derek Podhaizer maintains Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) with a Overweight and raises the price target from $37 to $50.

Piper Sandler Maintains Overweight on Solaris Energy, Raises Price Target to $50

On Friday, Co-Diagnostics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43895005/co-diagnostics-inc-announces-intention-to-submit-enhanced-version-of-covid-19-test-to-fda-for-510-" rel="noreferrer noopener">for 510(k) clearance</a>.
The company&#8217;s decision to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test related to shelf-life stability.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43890231/why-is-cancer-focused-exelixis-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?</a>
Following dialogue with the FDA and exploring the various courses of action available, Co-Dx has determined that the best long-term solution would be to submit an enhanced version of the test to address the matter raised in the 510(k) review process.&nbsp;
After collecting clinical evaluation data to support the new test&#8217;s performance, the company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance.
A new submission also allows the company to incorporate more recent&nbsp;Co-Dx PCR platform developments into the COVID-19 test, which Co-Dx believes will help create greater operational and manufacturing efficiencies. For example, it could consolidate manufacturing processes to utilize the next generation of test kits and instruments across all tests on the at-home and point-of-care platform.
The Co-Dx PCR COVID-19 test is expected to be followed by additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test, among others.
Price Action: CODX stock is down 14.9% at $0.60 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43894411/volkswagens-audi-to-grow-north-american-production-report" target="_blank" rel="noreferrer noopener">Volkswagen&#8217;s Audi To Grow North American Production: Report</a></li>
</ul>
Photo by Horth Rasuer via Shutterstock

Comments

Trane Technologies

ニュース

パートナーシップ

ベンジンガ・グローバル